

In the Claims

Claims 1-28 (Cancelled)

Claim 29 (New): A method for inducing proliferation of human or mouse stem cells, comprising introducing an inhibitor of murine s-SHIP activity or human s-SHIP (SIP-110) activity into the stem cells.

Claim 30 (New): The method of claim 29, wherein the inhibitor is a dominant-negative mutant.

Claim 31 (New): The method of claim 29, wherein the inhibitor is an anti-s-SHIP shRNA that reduces s-SHIP expression in the stem cells.

Claim 32 (New): The method of claim 31, wherein the shRNA is introduced into the stem cells by electroporation.

Claim 33 (New): The method of claim 32, wherein the stem cells are human stem cells, and wherein the shRNA reduces human s-SHIP (SIP-110) expression in the stem cells.

Claim 34 (New): The method of claim 32, wherein the stem cells are mouse cells, and wherein the shRNA reduces murine s-SHIP expression in the stem cells.

Claim 35 (New): The method of claim 32, wherein the stem cells are human stem cells, wherein the shRNA reduces human s-SHIP (SIP-110) expression in the stem cells, and wherein the human s-SHIP comprises the nucleotide sequence of SEQ ID NO:3.

Claim 36 (New): The method of claim 32, wherein the stem cells are mouse cells, wherein the shRNA reduces murine s-SHIP expression in the stem cells, and wherein the mouse s-SHIP comprises the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2.

Claim 37 (New): The method of claim 29, wherein the stem cells are human stem cells, and wherein the inhibitor inhibits human s-SHIP (SIP-110) activity in the stem cells.

Claim 38 (New): The method of claim 29, wherein the stem cells are mouse cells, and wherein the inhibitor inhibits murine s-SHIP activity in the stem cells.

Claim 39 (New): The method of claim 29, wherein the stem cells are embryonic stem cells.

Claim 40 (New): The method of claim 29, wherein the stem cells are hematopoietic stem cells.

Claim 41 (New): The method of claim 29, further comprising inducing the stem cells to differentiate.